Investors in Infinity Pharmaceuticals, Inc. INFI need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 17 th 2017 $3.00 Call had some of the highest implied volatility of all equity …
GAINERS 1. Infinity Pharmaceuticals Inc. (INFI) Gained 123.35% to close Thursday's (Oct.12) trading at $3.73. News: The Company will be reporting clinical and translational data from monotherapy dose-escalation component of its ongoing …
It has been about a month since the last earnings report for Infinity Pharmaceuticals, Inc. INFI. Shares have lost about 37.4% in that time frame, underperforming the market. Will the recent negative trend continue leading up to the stock's …
It may not reach its all-time highs any time soon, but even getting half its zenith would be a major boon for VRX stock. Another name among hard-hit pharma stocks is Infinity Pharmaceuticals Inc. (NASDAQ:INFI). Already flirting with …
Investors are likely punishing INFI's stock price, knowing that each delay pushes ... This is one of a few articles in a series by David Phillips highlighting "Drugs that Disappointed Investors in 2013," and what we can learn from the ride.
Infinity is an ideal candidate for a short sale. Infinity Pharmaceuticals (NASDAQ:INFI) has a short interest of 8%, which shows the generally positive mood on the Street for this stock. Despite the recent P2 failure of IPI-145 for RA, and its …
Admittedly, INFI stock is extremely speculative ... Article printed from InvestorPlace Media, https://investorplace.com/2016/08/3-troubled-pharma-stocks-could-rally-soon-vrx-infi-ptla/.